metricas
covid
Buscar en
Acta Otorrinolaringológica Española
Toda la web
Inicio Acta Otorrinolaringológica Española Neurofibromatosis type 2
Journal Information
Vol. 61. Issue 4.
Pages 306-311 (January 2010)
Share
Share
Download PDF
More article options
Vol. 61. Issue 4.
Pages 306-311 (January 2010)
Review
Full text access
Neurofibromatosis type 2
Neurofibromatosis tipo2
Visits
1021
Marta Pérez-Grau, Núria Miró, José Prades, Juan Vergés, Susana Lareo, Francesc Roca-Ribas
Corresponding author
12226frs@comb.cat

Corresponding author.
Unidad de Neurofibromatosis tipo 2, Servicio de ORL, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
This item has received
Article information
Abstract

Type 2 neurofibromatosis (NF2) is an invalidating, inherited, dominant, autosomal disease. It is commonly confused with type 1 neurofibromatosis, although the two disorders are different.

All subjects who inherit a mutated NF2 gene will develop the disease, which is characterised by the growth of schwannomas, generally affecting the vestibular nerve bilaterally, as well as meningiomas and other benign central nervous system tumours, before their third decade of life.

It is currently possible to identify the NF2 mutation in most affected families. Up to about 20% of NF2 patients with no family history, apparently sporadic cases, are actually individuals with mosaicism for this mutation.

Much of the morbidity from these tumours results from their treatment, which is primarily surgical. Small vestibular schwannomas can often be completely resected with preservation of both hearing and facial function. In case of large tumours it is possible to place a cochlear or brain stem implant during the schwannoma surgery.

Age at diagnosis, the presence of intracranial meningiomas and whether the patient was treated at a specialty centre or not have been cited as the strongest prognostic factors.

Keywords:
NF2
Vestibular schwannoma
Meningioma
Brain stem implant
Resumen

La neurofibromatosis tipo 2 es una enfermedad invalidante que se hereda de forma autosómica dominante. A menudo se ha confundido con la neurofibromatosis tipo 1, aunque son patologías distintas.

Todos los sujetos que hereden una mutación en el gen de la neurofibromatosis tipo 2 (NF2) desarrollarán dicha enfermedad, caracterizada por el crecimiento de schwanomas, habitualmente vestibulares y de forma bilateral, así como meningiomas u otros tumores benignos del sistema nervioso central, antes de los 30 años de edad.

Actualmente, podemos identificar la mutación del NF2 en la mayoría de las familias afectas. Hasta un 20% de los pacientes afectos de NF2 sin historia familiar, aparentemente casos esporádicos, son en realidad individuos con mosaicismo para esa mutación.

La morbilidad de esos tumores es en gran medida debida a su tratamiento, que es principalmente quirúrgico. Cuando son pequeños, los schwanomas vestibulares se pueden resecar completamente con preservación tanto de la función auditiva como facial. En caso de tumores grandes se puede colocar un implante coclear o bien de tronco cerebral durante el mismo acto quirúrgico.

Los principales factores pronósticos son: la edad media al diagnóstico, la presencia de meningiomas intracraneales y si el paciente fue tratado o no en un centro especializado.

Palabras clave:
Neurofibromatosis tipo 2
Schwanoma vestibular
Meningioma
Implante de tronco
Full text is only aviable in PDF
References
[1.]
B.R. Seizinger, G.A. Rouleau, L.G. Ozelius, A.H. Lane, A.G. Faryniarz, M.V. Chao, et al.
Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene.
Cell, 49 (1987), pp. 589-594
[2.]
G. Rouleau, B.R. Seizinger, W. Wertelecki, J.L. Haines, D.W. Superneau, R.L. Martuza, et al.
Genetic linkage analysis of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22.
Nature, 329 (1987), pp. 246-248
[3.]
D.G. Evans, A. Moran, A. King, S. Saeed, N. Gurusinghe, R. Ramsden.
Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought.
Otol Neurotol, 26 (2005), pp. 93-97
[4.]
D.H. Gutmann, L. Sherman, L. Seftor, C. Haipek, K.H. Lu, M. Hendrix.
Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesion and spreading.
Hum Mol Genet, 8 (1999), pp. 267-275
[5.]
M.E. Baser, J.M. Friedman, D. Aeschliman, H. Joe, A.J. Wallace, R.T. Ramsden, et al.
Predictors of the risk of mortality in neurofibromatosis 2.
Am J Hum Genet, 71 (2002), pp. 715-723
[6.]
D.G. Evans, M.E. Baser, B. O’Reilly, J. Rowe, M. Gleeson, S. Saeed, et al.
Management of the patient and family with neurofibromatosis 2: a consensus conference statement.
Br J Neurosurg, 19 (2005), pp. 5-12
[7.]
M. Ruggieri, P. Iannetti, A. Polizzi, I. La Mantia, A. Spalice, O. Giliberto, et al.
Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.
Neuropediatrics, 36 (2005), pp. 21-34
[8.]
G. Dow, N. Biggs, G. Evans, J. Gillespie, R. Ramsden, A. King.
Spinal tumors in neurofibromatosis type 2. Is emerging knowledge of genotype predictive of natural history?.
J Neurosurg Spine, 2 (2005), pp. 574-579
[9.]
A. Perry, C. Giannini, R. Raghavan, B.W. Scheithauer, R. Banerjee, L. Margraf, et al.
Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases.
J Neuropathol Exp Neurol, 60 (2001), pp. 994-1003
[10.]
D.G. Evans, J.M. Birch, R.T. Ramsden.
Paediatric presentation of type 2 neurofibromatosis.
Arch Dis Child, 81 (1999), pp. 496-499
[11.]
A.D. Sperfeld, C. Hein, J.M. Schroder, A.C. Ludolph, C.O. Hanemann.
Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2.
Brain, 125 (2002), pp. 996-1004
[12.]
National Institutes of Health Consensus Development Conference.
Statement on neurofibromatosis.
Arch Neurol, 45 (1987), pp. 575-579
[13.]
A. Moyhuddin, M.E. Baser, C. Watson, S. Purcell, R.T. Ramsden, A. Heiberg, et al.
Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring.
J Med Genet, 40 (2003), pp. 459-463
[14.]
D.G. Evans, R.T. Ramsden, C. Gokhale, N. Bowers, S.M. Huson, A. Wallace.
Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?.
Clin Genet, 71 (2007), pp. 354-358
[15.]
M.E. Baser, J.M. Friedman, D.G. Evans.
Increasing the specificity of diagnostic criteria for schwannomatosis.
[16.]
D.G. Evans, R.T. Ramsden, A. Shenton, C. Gokhale, N.L. Bowers, S.M. Huson, et al.
Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification.
J Med Genet, 44 (2007), pp. 424-428
[17.]
L. Kluwe, V. Mautner, B. Heinrich, R. Dezube, L.B. Jacoby, R.E. Friedrich, et al.
Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas.
J Med Genet, 40 (2003), pp. 109-114
[18.]
D.G. Evans, A.J. Wallace, C.L. Wu, L. Trueman, R.T. Ramsden, T. Strachan.
Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis.
Am J Hum Genet, 63 (1998), pp. 727-736
[19.]
M.E. Baser, D.G. Evans, R.K. Jackler, et al.
Neurofibromatosis 2, radiosurgery and malignant nervous system tumours.
Br J Cancer, 82 (2000), pp. 998
[20.]
J.G. Rowe, M.W. Radatz, L. Walton, T. Soanes, J. Rodgers, A.A. Kemeny.
Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis.
J Neurol Neurosurg Psychiatry, 74 (2003), pp. 1288-1293
[21.]
M.E. Baser, J.M. Friedman, D. Aeschliman, et al.
Predictors of the risk of mortality in neurofibromatosis 2.
Am J Hum Genet, 71 (2002), pp. 715-723
[22.]
A.R. Asthagiri, D.M. Parry, J.A. Butman, H.J. Kim, E.T. Tsilou, Z. Zhuang, et al.
Neurofibromatosis type 2.
Lancet, 373 (2009), pp. 1974-1986
Copyright © 2010. Sociedad Española de Otorrinolaringología y Patología Cérvico-Facial
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos